Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 program for ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Next Previous
Trial Profile

A phase 3 program for ATTR amyloidosis with cardiomyopathy (ATTR-CM)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Coramitug (Primary)
  • Indications Transthyretin-related hereditary amyloidosis
  • Focus Therapeutic Use

Most Recent Events

  • 03 Oct 2025 New trial record
  • 06 Aug 2025 According to the Prothena Media Release, company is eligible to receive up to $1.2 billion dollars upon achievement of clinical development and sales milestones, including the $100 million earned to date. Prothena is eligible to earn a clinical milestone payment when prespecified enrollment criteria are met in the Phase 3 clinical trial.
  • 06 Aug 2025 According to the Prothena Media Release, expected to initiate a Phase 3 program in 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top